Stephens analyst Scott Fidel lowered the firm’s price target on Addus HomeCare (ADUS) to $135 from $140 and keeps an Overweight rating on the shares. The firm trimmed out-year estimates following the company’s Q4 report, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus HomeCare Earnings Call Highlights Growth And Scale
- Addus HomeCare falls -12.4%
- Addus HomeCare price target lowered to $112 from $117 at Barclays
- Addus Homecare: Strong Core Growth, Expanding Margins, and Upside from Hospice Momentum Support Buy Rating
- Addus HomeCare Reports Strong Q4 and Full-Year Results